DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Effect of Glucagon on Uterine Contractility at the Time of Embryo Transfer in in Vitro Fertilization

Information source: OVO R & D
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Women With Fertility Disorder

Intervention: Glucagon (Drug); placebo (Drug)

Phase: Phase 4

Status: Withdrawn

Sponsored by: OVO R & D

Official(s) and/or principal investigator(s):
Eric Himaya, Dr, Principal Investigator, Affiliation: clinique ovo and CHUM


The success of in vitro fertilization is based mainly on uterine implantation embryo. An excessive uterine contractility may interfere with implantation by a movement of the embryo in the uterus. The inhibition of the uterine contractility may have a positive effect on success rate of in vitro fertilization. It is through parenteral injection of glucagon and its spasmolytic effect on various smooth muscles and thereby on the uterine muscle, at the time of embryo transfer, the investigators intend to improve the pregnancy rates obtained after IVF.

Clinical Details

Official title: Effect of Glucagon on Uterine Contractility at the Time of Embryo Transfer in in Vitro Fertilization

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Primary outcome: Uterine muscle relaxation

Secondary outcome: Embryo implantation and pregnancy rate

Detailed description: Women will have a cycle of in vitro fertilization (IVF) and follow the standard protocol established by the clinic ovo or the fertility clinic of CHUM. On the day of embryo transfer, the investigators will administer 1 mg of Glucagon or placebo intramuscularly 10 minutes before the embryo transfer. The uterine contractility will be measured by ultrasound before and after injection to document the impact of Glucagon on it and we will proceed to embryo transfer.


Minimum age: 18 Years. Maximum age: 40 Years. Gender(s): Female.


Inclusion Criteria:

- Women doing fertility treatment at the clinic ovo or fertility clinic of CHUM

- Less than 40 years old

- Women with stimulate in vitro fertilization cycle

- Women able to give her consent

Exclusion Criteria:

- Body mass index > 35 kg/m2

- Women with diabetes

- Women with hypertensive disorders

- Women with a blood pressure greater or equal to 140/90 mmHg at the randomization


- Cons-indication to taking Glucagon:

- Hypersensitivity to product

- Pheochromocytoma or history of pheochromocytoma

- Insulinoma

- Taking a beta-blocker (drug interactions)

Locations and Contacts

Clinique Ovo, Montréal, Quebec H4P 2S4, Canada
Additional Information

Starting date: October 2013
Last updated: July 24, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017